Group 1 - The core viewpoint of the article highlights the growth of the insurance industry in Shenzhen, with a total original insurance premium income of 191.045 billion yuan from January to October 2025, representing a year-on-year increase of 12.2% [1] - Among different types of insurance, life insurance accounted for the highest share, totaling 101.571 billion yuan, which is 53.17% of the total premium income [1] - The report referenced is the "2026-2032 China Insurance Industry Development Analysis and Investment Prospect Forecast Report" published by Zhiyan Consulting, indicating a focus on future growth and investment opportunities in the insurance sector [1] Group 2 - The data source for the insurance premium statistics is the National Financial Supervision Administration, organized by Zhiyan Consulting, emphasizing the credibility of the information [1] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in in-depth industry research reports, business plans, feasibility studies, and customized services [1] - The firm aims to provide comprehensive industry solutions to empower investment decisions through professional insights and quality services [1]

相关报告：智研咨询发布的《2026-2032年中国保险行业发展分析及投资前景预测报告》 2025年1-10月贵州省原保险保费收入共计522.81亿元，同比增长4.61%，贵州省累计原保险保费收入不 同险种类别中寿险占比最高，为202.45亿元，占比38.72%。 2020年-2025年1-10月贵州省累计原保险保费收入统计图 上市企业：天茂集团（000627），中国平安（601318），中国人保（601319），新华保险（601336）， 中国太保（601601），中国人寿（601628） 数据来源：国家金融监督管理总局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 ...

Group 1 - The core viewpoint of the article highlights the growth of the insurance industry in Gansu Province, with a total original insurance premium income of 51.404 billion yuan from January to October 2025, representing a year-on-year increase of 3.62% [1] - Life insurance accounted for the highest share of the total original insurance premium income in Gansu Province, amounting to 27.834 billion yuan, which is 54.15% of the total [1] - The article references a report by Zhiyan Consulting that analyzes the development and investment prospects of the Chinese insurance industry from 2026 to 2032 [1] Group 2 - Listed companies mentioned include Tianmao Group, China Ping An, China Pacific Insurance, China Life, China People’s Insurance, and Xinhua Insurance [1] - The data source for the insurance premium statistics is the National Financial Supervision Administration, organized by Zhiyan Consulting [1] - Zhiyan Consulting is described as a leading industry consulting firm in China, providing comprehensive industry research reports and customized services for investment decision-making [1]

Group 1 - The core viewpoint of the article highlights the growth of the insurance industry in Shaanxi Province, with a total original insurance premium income of 127.97 billion yuan from January to October 2025, representing a year-on-year increase of 6.11% [1] - Life insurance accounted for the highest proportion of the total original insurance premium income in Shaanxi Province, amounting to 80.52 billion yuan, which is 62.92% of the total [1] - The report referenced is the "2026-2032 China Insurance Industry Development Analysis and Investment Prospect Forecast Report" published by Zhiyan Consulting, indicating a focus on future growth and investment opportunities in the insurance sector [1] Group 2 - The article lists several publicly listed companies in the insurance sector, including Tianmao Group, China Ping An, China Pacific Insurance, China Life, and others, suggesting a competitive landscape [1] - Zhiyan Consulting is described as a leading industry consulting firm in China, emphasizing its expertise in providing in-depth industry research reports and tailored consulting services [1]

数据来源：国家金融监督管理总局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 2025年1-10月云南省原保险保费收入共计816.73亿元，同比增长5.52%，云南省累计原保险保费收入不 同险种类别中寿险占比最高，为384.23亿元，占比47.04%。 2020年-2025年1-10月云南省累计原保险保费收入统计图 上市企业：天茂集团（000627），中国平安（601318），中国人保（601319），新华保险（601336）， 中国太保（601601），中国人寿（601628） 相关报告：智研咨询发布的《2026-2032年中国保险行业发展分析及投资前景预测报告》 ...

数据来源：国家金融监督管理总局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 2025年1-10月海南省原保险保费收入共计196.14亿元，同比增长3.61%，海南省累计原保险保费收入不 同险种类别中寿险占比最高，为92.03亿元，占比46.92%。 2020年-2025年1-10月海南省累计原保险保费收入统计图 上市企业：天茂集团（000627），中国平安（601318），中国人保（601319），新华保险（601336）， 中国太保（601601），中国人寿（601628） 相关报告：智研咨询发布的《2026-2032年中国保险行业发展分析及投资前景预测报告》 ...

2020年-2025年1-10月广西壮族自治区累计原保险保费收入统计图 数据来源：国家金融监督管理总局，智研咨询整理 上市企业：天茂集团（000627），中国平安（601318），中国人保（601319），新华保险（601336）， 中国太保（601601），中国人寿（601628） 相关报告：智研咨询发布的《2026-2032年中国保险行业发展分析及投资前景预测报告》 2025年1-10月广西壮族自治区原保险保费收入共计790.42亿元，同比增长2.52%，广西壮族自治区累计 原保险保费收入不同险种类别中寿险占比最高，为383.29亿元，占比48.49%。 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 ...

2025年1-10月四川省原保险保费收入共计2645.15亿元，同比增长5.5%，四川省累计原保险保费收入不 同险种类别中寿险占比最高，为1522.04亿元，占比57.54%。 2020年-2025年1-10月四川省累计原保险保费收入统计图 数据来源：国家金融监督管理总局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市企业：天茂集团（000627），中国平安（601318），中国人保（601319），新华保险（601336）， 中国太保（601601），中国人寿（601628） 相关报告：智研咨询发布的《2026-2032年中国保险行业发展分析及投资前景预测报告》 ...

Core Viewpoint - The insurance premium income in Chongqing for the period from January to October 2025 reached 111.76 billion yuan, marking a year-on-year growth of 8.07%, with life insurance accounting for the largest share at 67.589 billion yuan, representing 60.48% of the total [1]. Group 1: Company Insights - Tianmao Group (000627), China Ping An (601318), China Pacific Insurance (601601), China Life (601628), China Insurance (601319), and Xinhua Insurance (601336) are key players in the insurance sector [1]. - The report by Zhiyan Consulting provides an analysis of the development and investment prospects of the Chinese insurance industry from 2026 to 2032 [1]. Group 2: Industry Data - The cumulative original insurance premium income in Chongqing from 2020 to October 2025 is documented, highlighting the growth trends in various insurance categories [1]. - Life insurance has the highest proportion of premium income in Chongqing, indicating a strong market preference for this type of insurance [1].

Core Insights - The incidence of acute gout is rising globally, particularly among younger populations aged 18-35, who account for nearly 60% of cases, with a significantly higher male-to-female ratio [1][5] - By 2024, the global number of acute gout patients is expected to reach 45.4 million, with China contributing approximately 19.4 million cases; this number is projected to increase to 47.7 million globally and 22.2 million in China by 2025 [1][5] - The global acute gout drug market is expected to stabilize around $1.5 billion by 2025, with China's market size estimated at $0.1 billion [1][5] Industry Definition and Classification - Gout is a type of crystal arthritis caused by purine metabolism disorders or reduced uric acid excretion, primarily characterized by the deposition of monosodium urate crystals [2][3] - Treatment options are categorized into two main types: drugs for acute gout attacks and uric acid-lowering drugs [3][4] Current Industry Status - The acute gout drug market has remained stable despite rising patient numbers due to price increases leading to decreased sales volume [5] - The need for effective treatment is critical as uncontrolled acute attacks can lead to increased frequency and severity, impacting patients' quality of life [5] Industry Chain - The upstream of the acute gout drug industry includes raw materials, intermediates, and production equipment; the midstream focuses on drug R&D and production, while the downstream involves distribution channels and end patients [6] Regulatory Environment - The Chinese government has been enhancing policy guidance and regulation in the acute gout drug industry through various healthcare and drug management policies to promote healthy industry development [6] Competitive Landscape - Major competitors in the acute gout drug market include companies like Haichuang Pharmaceutical, Heng Rui Medicine, Yifang Bio, and Yipinhong, which are actively developing clinical pipelines for hyperuricemia and gout treatments [7][8] - The market is characterized by a strong demand for new, safe uric acid-lowering drugs, as existing treatments do not fully meet clinical needs [7] Development Trends - The acute gout drug industry in China is rapidly evolving, with market expansion and increasing competition driven by policy support, technological advancements, and market demand [10] - The industry is moving towards more precise, effective, and personalized treatment options, with a focus on domestic alternatives to improve patient outcomes [10]